Which has better earnings and valuation, IMA or HIND?

Vyome has lower revenue, but higher earnings than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImageneBio $800K 82.86 -$45.35M -$4.58 N/A Vyome $320K 47.82 -$10.26M -$12.27 N/A

Is IMA or HIND more profitable?

ImageneBio has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. ImageneBio's return on equity of -38.99% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.99% -34.84% Vyome -3,024.84% -197.33% -138.14%

Do analysts rate BOLD or HIND?

Vyome has a consensus target price of $15.00, suggesting a potential upside of 588.07%. Given Vyome's stronger consensus rating and higher probable upside, analysts plainly believe Vyome is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vyome 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger earnings & valuation, BOLD or HIND?

Vyome has higher revenue and earnings than Boundless Bio. Boundless Bio is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boundless Bio N/A N/A -$58.20M -$2.86 N/A Vyome $320K 47.82 -$10.26M -$12.27 N/A

Is BOLD or HIND more profitable?

Boundless Bio has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Boundless Bio's return on equity of -70.89% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets Boundless Bio N/A -70.89% -47.37% Vyome -3,024.84% -197.33% -138.14%

Is ELTX or HIND more profitable?

Elicio Therapeutics has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Vyome's return on equity of -197.33% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -2,827.47% -147.75% Vyome -3,024.84% -197.33% -138.14%

Do analysts prefer XLO or HIND?

Vyome has a consensus target price of $15.00, suggesting a potential upside of 588.07%. Given Vyome's stronger consensus rating and higher possible upside, analysts plainly believe Vyome is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vyome 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is XLO or HIND more profitable?

Xilio Therapeutics has a net margin of -34.06% compared to Vyome's net margin of -3,024.84%. Xilio Therapeutics' return on equity of -71.99% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets Xilio Therapeutics -34.06% -71.99% -20.43% Vyome -3,024.84% -197.33% -138.14%

Which has stronger earnings and valuation, HIND or IMMP?

Vyome has higher earnings, but lower revenue than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vyome $320K 47.82 -$10.26M -$12.27 N/A Prima BioMed $6.69M 8.37 -$39.78M N/A N/A

Is HIND or IMMP more profitable?

Prima BioMed has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Prima BioMed's return on equity of 0.00% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets Vyome -3,024.84% -197.33% -138.14% Prima BioMed N/A N/A N/A

Vyome (HIND) Competitors

$2.18 +0.02 (+0.93%)

Closing price 04:00 PM Eastern

Extended Trading

$2.17 -0.01 (-0.32%)

As of 07:55 PM Eastern

Compare

HIND vs. IMA, BOLD, ELTX, XLO, and IMMP

Should you buy Vyome stock or one of its competitors? Vyome's main competitors and comparable companies include ImageneBio (IMA), Boundless Bio (BOLD), Elicio Therapeutics (ELTX), Xilio Therapeutics (XLO), and Prima BioMed (IMMP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vyome compare to ImageneBio?

ImageneBio (NASDAQ:IMA) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

ImageneBio has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. ImageneBio's return on equity of -38.99% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Vyome	-3,024.84%	-197.33%	-138.14%

In the previous week, Vyome had 1 more articles in the media than ImageneBio. MarketBeat recorded 2 mentions for Vyome and 1 mentions for ImageneBio. ImageneBio's average media sentiment score of 1.87 beat Vyome's score of 1.47 indicating that ImageneBio is being referred to more favorably in the media.

Company	Overall Sentiment
ImageneBio	Very Positive
Vyome	Positive

Vyome has lower revenue, but higher earnings than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	82.86	-$45.35M	-$4.58	N/A
Vyome	$320K	47.82	-$10.26M	-$12.27	N/A

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 22.1% of Vyome shares are held by institutional investors. 2.2% of ImageneBio shares are held by insiders. Comparatively, 33.0% of Vyome shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ImageneBio presently has a consensus price target of $30.00, suggesting a potential upside of 413.70%. Vyome has a consensus price target of $15.00, suggesting a potential upside of 588.07%. Given Vyome's stronger consensus rating and higher possible upside, analysts clearly believe Vyome is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

ImageneBio has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Vyome has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

Summary

ImageneBio beats Vyome on 9 of the 16 factors compared between the two stocks.

How does Vyome compare to Boundless Bio?

Boundless Bio (NASDAQ:BOLD) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Boundless Bio has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Boundless Bio's return on equity of -70.89% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-70.89%	-47.37%
Vyome	-3,024.84%	-197.33%	-138.14%

Boundless Bio has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market. Comparatively, Vyome has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

22.1% of Vyome shares are owned by institutional investors. 23.1% of Boundless Bio shares are owned by company insiders. Comparatively, 33.0% of Vyome shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vyome has a consensus target price of $15.00, suggesting a potential upside of 588.07%. Given Vyome's stronger consensus rating and higher probable upside, analysts plainly believe Vyome is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Vyome has higher revenue and earnings than Boundless Bio. Boundless Bio is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A
Vyome	$320K	47.82	-$10.26M	-$12.27	N/A

In the previous week, Vyome had 1 more articles in the media than Boundless Bio. MarketBeat recorded 2 mentions for Vyome and 1 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 1.47 equaled Vyome'saverage media sentiment score.

Company	Overall Sentiment
Boundless Bio	Positive
Vyome	Positive

Summary

Vyome beats Boundless Bio on 9 of the 13 factors compared between the two stocks.

How does Vyome compare to Elicio Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 22.1% of Vyome shares are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by insiders. Comparatively, 33.0% of Vyome shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Elicio Therapeutics presently has a consensus target price of $19.75, indicating a potential upside of 539.16%. Vyome has a consensus target price of $15.00, indicating a potential upside of 588.07%. Given Vyome's higher probable upside, analysts clearly believe Vyome is more favorable than Elicio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Elicio Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Vyome has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Vyome has higher revenue and earnings than Elicio Therapeutics. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A
Vyome	$320K	47.82	-$10.26M	-$12.27	N/A

In the previous week, Elicio Therapeutics had 4 more articles in the media than Vyome. MarketBeat recorded 6 mentions for Elicio Therapeutics and 2 mentions for Vyome. Vyome's average media sentiment score of 1.47 beat Elicio Therapeutics' score of 0.70 indicating that Vyome is being referred to more favorably in the news media.

Company	Overall Sentiment
Elicio Therapeutics	Positive
Vyome	Positive

Elicio Therapeutics has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Vyome's return on equity of -197.33% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,827.47%	-147.75%
Vyome	-3,024.84%	-197.33%	-138.14%

Summary

Elicio Therapeutics and Vyome tied by winning 7 of the 14 factors compared between the two stocks.

How does Vyome compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

In the previous week, Xilio Therapeutics had 3 more articles in the media than Vyome. MarketBeat recorded 5 mentions for Xilio Therapeutics and 2 mentions for Vyome. Vyome's average media sentiment score of 1.47 beat Xilio Therapeutics' score of 0.60 indicating that Vyome is being referred to more favorably in the news media.

Company	Overall Sentiment
Xilio Therapeutics	Positive
Vyome	Positive

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 22.1% of Vyome shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by company insiders. Comparatively, 33.0% of Vyome shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Vyome has a consensus target price of $15.00, suggesting a potential upside of 588.07%. Given Vyome's stronger consensus rating and higher possible upside, analysts plainly believe Vyome is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Xilio Therapeutics has a net margin of -34.06% compared to Vyome's net margin of -3,024.84%. Xilio Therapeutics' return on equity of -71.99% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-34.06%	-71.99%	-20.43%
Vyome	-3,024.84%	-197.33%	-138.14%

Xilio Therapeutics has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market. Comparatively, Vyome has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

Vyome has lower revenue, but higher earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.38	-$35.04M	-$3.55	N/A
Vyome	$320K	47.82	-$10.26M	-$12.27	N/A

Summary

Vyome beats Xilio Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Vyome compare to Prima BioMed?

Vyome (NASDAQ:HIND) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

22.1% of Vyome shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 33.0% of Vyome shares are owned by insiders. Comparatively, 3.1% of Prima BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Prima BioMed had 1 more articles in the media than Vyome. MarketBeat recorded 3 mentions for Prima BioMed and 2 mentions for Vyome. Vyome's average media sentiment score of 1.47 beat Prima BioMed's score of 1.21 indicating that Vyome is being referred to more favorably in the media.

Company	Overall Sentiment
Vyome	Positive
Prima BioMed	Positive

Vyome has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market.

Vyome has higher earnings, but lower revenue than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	47.82	-$10.26M	-$12.27	N/A
Prima BioMed	$6.69M	8.37	-$39.78M	N/A	N/A

Prima BioMed has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Prima BioMed's return on equity of 0.00% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-3,024.84%	-197.33%	-138.14%
Prima BioMed	N/A	N/A	N/A

Vyome presently has a consensus price target of $15.00, suggesting a potential upside of 588.07%. Prima BioMed has a consensus price target of $5.50, suggesting a potential upside of 1,347.37%. Given Prima BioMed's higher possible upside, analysts clearly believe Prima BioMed is more favorable than Vyome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Vyome and Prima BioMed tied by winning 7 of the 14 factors compared between the two stocks.

Get Vyome News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HIND vs. The Competition

Export

Metric	Vyome	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.16M	$3.71B	$6.98B	$13.04B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	N/A	10.68	269.86	25.30
Price / Sales	47.82	1,308.25	601.81	101.06
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	2.10	17.49	13.08	6.33
Net Income	-$10.26M	-$13.32M	$3.45B	$347.70M
7 Day Performance	-0.91%	1.74%	1.12%	1.07%
1 Month Performance	N/A	1.60%	1.79%	1.03%
1 Year Performance	N/A	56.43%	67.69%	20.77%

Vyome Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HIND Vyome	3.2687 of 5 stars	$2.18 +0.9%	$15.00 +588.1%	N/A	$15.16M	$320K	N/A	50	Positive News Earnings Report
IMA ImageneBio	2.7441 of 5 stars	$5.75 +0.7%	$30.00 +421.7%	-58.7%	$60.84M	$800K	N/A	70	Positive News
BOLD Boundless Bio	1.8138 of 5 stars	$2.82 +4.5%	$4.00 +41.7%	+136.6%	$60.76M	N/A	N/A	64	Earnings Report High Trading Volume
ELTX Elicio Therapeutics	3.1248 of 5 stars	$3.19 +0.9%	$19.75 +519.1%	-66.5%	$60.31M	N/A	N/A	N/A	News Coverage Earnings Report
XLO Xilio Therapeutics	0.0901 of 5 stars	$9.11 +0.2%	N/A	-10.0%	$59.77M	$43.77M	N/A	70	Earnings Report Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HIND) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vyome (HIND) Competitors